{"id":58594,"date":"2023-09-08T13:56:30","date_gmt":"2023-09-08T17:56:30","guid":{"rendered":"https:\/\/ifintechworld.com\/news\/aviditys-teetering-dance-balancing-aoc-promises-and-puzzles-nasdaqrna\/"},"modified":"2023-09-08T13:56:37","modified_gmt":"2023-09-08T17:56:37","slug":"aviditys-teetering-dance-balancing-aoc-promises-and-puzzles-nasdaqrna","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=58594","title":{"rendered":"Avidity\u2019s Teetering Dance: Balancing AOC Promises And Puzzles (NASDAQ:RNA)"},"content":{"rendered":"
\n

<\/picture>
<\/figcaption><\/figure>\n<\/p>\n

Introduction<\/h2>\n

Avidity<\/strong> (NASDAQ:RNA<\/span>) is a biopharmaceutical firm specializing in a unique RNA therapy termed Antibody Oligonucleotide Conjugates (AOCs). This platform fuses the exactness of RNA therapeutics with monoclonal antibodies, targeting previously untreatable diseases. Currently, three AOC programs are undergoing clinical trials, focusing on various muscular dystrophies.<\/span><\/p>\n

In a recent analysis, I concluded that Avidity offers a promising AOC platform targeting untreatable diseases. Their three clinical programs could<\/em> lead to revolutionary treatments. The stock’s volatility stemmed from trial setbacks and the inherent risks of novel therapies. Upcoming trial data and FDA interactions are crucial. Their financial sustainability requires close monitoring, and given the uncertainties, I recommended a ‘Hold’ stance on their stock.<\/p>\n

The following article discusses Avidity’s financial health, ongoing clinical trials, and its recent FDA interactions concerning AOC 1001, suggesting a “Hold” investment position.<\/p>\n

Q2 Earnings Report<\/span> <\/h2>\n

Looking at Avidity’s most recent earnings report, as of June 30, 2023, they held $576.5M in cash and equivalents, a decrease from $610.7M at the end of 2022. Collaboration revenue, largely from their partnership with Eli Lilly (LLY), amounted to $2.3M for Q2 2023, slightly up from $2.2M in Q2 2022. R&D expenses rose to $42.6M in Q2 2023 from $39.8M in Q2 2022, with the increase attributed to the advancement of specific research projects and expansion of overall capabilities. G&A expenses also increased to $12.3M in Q2 2023, up from $8.7M in Q2 2022, due to higher personnel and professional fees supporting expanded operations.<\/p>\n

Cash Runway & Liquidity<\/strong><\/h2>\n

Turning to Avidity’s balance sheet, as of June 30, 2023, the company has combined assets of $576.5M in ‘Cash and cash equivalents’ ($153.9M) and ‘Marketable securities’ ($422.6M). Over the span of six months ending June 30, 2023, the “Net cash used in operating activities” was $98.8M, leading to an estimated monthly cash burn of $16.5M. Given this rate, the company has a cash runway of approximately 34.9 months based on the combined assets. It’s important to note, however, that these values and estimates are grounded in past data, and their relevance to future performance is uncertain.<\/p>\n

In assessing Avidity’s liquidity status, the significant presence of assets in the form of cash and marketable securities indicates a strong liquidity position, allowing them to cover their operational expenses for the foreseeable future. The company doesn’t appear to have significant debt. Given the company’s healthy liquidity position and the continued capability to raise capital through common stock issuances, as seen in recent history, it seems probable that Avidity could secure additional financing if required. These are my personal observations, and other analysts might interpret the data differently.<\/p>\n

Valuation, Growth, & Momentum<\/strong><\/h2>\n

According to Seeking Alpha data, Avidity’s capital structure reveals a minimal debt relative to its market capitalization, with an enterprise value at -$52.76M. Valuation metrics are primarily not applicable due to the company’s developmental phase. Though the company is generating minimal revenue via collaborations, the growth prospects remain favorable given its yearly revenue growth and consistent 3-year compound annual growth rate (CAGR). Avidity’s stock momentum is significantly underperforming broader market indices.<\/p>\n

\n

\"Chart\"
Data by YCharts<\/figcaption><\/figure>\n<\/p>\n

Flexing Forward: Avidity’s Prowess in Muscle Disease Research<\/h2>\n

Avidity is making significant strides in the realm of rare muscle diseases, especially DM1, DMD, and FSHD. Their intensive research promises transformative treatments for these conditions.<\/p>\n

In the Phase 1\/2 MARINA trial, AOC 1001’s intravenous administration was evaluated for its safety and tolerability in adults with DM1. This involved a 3:1 randomized study of 38 participants. The results revealed directional improvements in multiple functional assessments. Myotonia, a DM1 hallmark, was assessed via video hand opening time (vHOT), strength was measured using the Quantitative Muscle Testing (QMT) total score from various muscle groups, and mobility was gauged through the 10-meter walk run test and the Timed Up and Go test. Importantly, these functional measurements are closely aligned with the ongoing END-DM1 natural history study.<\/p>\n

Additionally, the study indicated substantial DMPK reduction and gene splicing changes with AOC 1001 treatment. Broad splicing improvements were observed across over a thousand genes linked to DM1, underscoring its nuclear activity. Furthermore, AOC 1001 exhibited a commendable safety and tolerability profile, with most adverse effects being mild to moderate.<\/p>\n

Other milestones include the initiation of the AOC 1044 EXPLORE44 trial for Duchenne muscular dystrophy and the FDA’s easing of the partial clinical hold for AOC 1001.<\/p>\n

My Analysis & Recommendation<\/strong><\/h2>\n

Avidity, with its innovative AOC platform, has garnered attention in the biopharmaceutical domain, particularly for its potential to address diseases previously deemed untreatable. A key point of contemplation, however, remains the company’s current negative enterprise value of -$52.76M.<\/p>\n

Factors warranting consideration include:<\/p>\n